Drug evaluation: Bevirimat - HIV Gag protein and viral maturation inhibitor

Zelalem Temesgen, Judith E. Feinberg

Research output: Contribution to journalReview article

14 Scopus citations

Abstract

Panacos Pharmaceuticals Inc is developing the HIV Gag protein and viral maturation inhibitor bevirimat for the potential oral treatment of HIV infection. Phase II clinical trials are underway and phase III trials expected to commence in 2007.

Original languageEnglish (US)
Pages (from-to)759-765
Number of pages7
JournalCurrent Opinion in Investigational Drugs
Volume7
Issue number8
StatePublished - Aug 1 2006

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Drug evaluation: Bevirimat - HIV Gag protein and viral maturation inhibitor'. Together they form a unique fingerprint.

  • Cite this